brand logo

Am Fam Physician. 2021;103(10):630-631

Clinical Question

What effect do sodium-glucose cotransporter-2 (SGLT2) inhibitors have on mortality and cardiovascular and renal outcomes in patients with and without diabetes mellitus, heart failure, or kidney disease?

Bottom Line

SGLT2 inhibitors—medications ending in -flozin, such as canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro)—reduce all-cause and cardiovascular mortality in patients regardless of the presence of type 2 diabetes, heart failure, or chronic kidney disease. Similar mortality reduction occurs in patients with diabetes regardless of comorbid heart failure, and in patients with heart failure regardless of the presence of diabetes. SGLT2 inhibitors also reduce the progression of renal disease in all patients. (Level of Evidence = 1a–)

Synopsis

Two researchers independently searched three databases, including Cochrane CENTRAL, with the bibliographies of identified studies and abstracts of major cardiology meetings, to identify randomized studies in any language that evaluated the impact of treatment with an SGLT2 inhibitor in patients with or without heart failure or type 2 diabetes. Two researchers independently abstracted the data. The researchers followed PRISMA guidelines and assessed the quality of evidence. They included eight studies of 59,747 patients, comprising three studies that included patients without diabetes. Treatment with an SGLT2 inhibitor reduced the risk of mortality due to all causes (hazard ratio [HR] = 0.84; 95% CI, 0.78 to 0.91), cardiovascular mortality (HR = 0.84; 95% CI, 0.76 to 0.93), and hospitalization for heart failure (HR = 0.69; 95% CI, 0.64 to 0.74) compared with placebo, and reduced a composite of end-stage kidney disease, a doubling of the serum creatinine level, and kidney-related mortality (HR = 0.62; 95% CI, 0.56 to 0.70). There were similar mortality and renal benefits for patients with or without diabetes and patients with or without heart failure. Heterogeneity among study results was moderate for mortality outcomes and low for heart failure hospitalization and kidney outcomes.

Study design: Meta-analysis (randomized controlled trials)

Funding source: Self-funded or unfunded

Setting: Various (meta-analysis)

Reference:SalahHMAl'ArefSJKhanMSet alEffect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes–systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J2020;232:10–22.

Editor's Note: Dr. Shaughnessy is an assistant medical editor for AFP.

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.